<unk> , sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate.<unk>  refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. The most common side effects are fatigue, peripheral neuropathy (nerve damage resulting in tingling or numbness), decreased appetite, rash, alopecia (hair loss), nausea, altered taste, diarrhea, dry eye, pruritus (itching) and dry skin. The fully humanized antibody was created by scientists at Agensys (part of Astellas) using Xenomice from Amgen; the linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Enfortumab vedotin
Sacituzumab govitecan
Tisotumab vedotin
Loncastuximab tesirine
Polatuzumab vedotin
Acalabrutinib
Lanadelumab
Selpercatinib